Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZKYNO)

Drug Name
Juvidex Drug Info
Synonyms Adaprev; Mannose-6-phosphate (scarring), Renovo
Indication
Disease Entry ICD 11 Status REF
Sarcoidosis 4B20.5 Phase 2 [1]
Cross-matching ID
PubChem CID
6101690
ChEBI ID
CHEBI:48042
CAS Number
CAS 3672-15-9
TTD Drug ID
DMZKYNO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting CI Man-6-P receptor (IGF2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PXS-25 DMVQJOS Fibrosis GA14-GC01 Phase 1 [3]
EP-128504 DMJEKQM Solid tumour/cancer 2A00-2F9Z Preclinical [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CI Man-6-P receptor (IGF2R) TTPNE41 MPRI_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00984516) Investigation Into the Safety and Scar-improvement Efficacy of Intradermal Juvidex Dosed Once or Three Times. U.S. National Institutes of Health.
2 Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Mol Med. 2011 Jan-Feb; 17(1-2): 113-125.
3 Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1. Am J Physiol Renal Physiol.2011 Jul;301(1):F84-93.
4 The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach. Mol Cancer Ther. 2005 May;4(5):761-71.